RT Journal Article
T1 Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy
A1 Rodríguez-Martínez, Alba
A1 de Miguel-Pérez, Diego
A1 Ortega, Francisco Gabriel
A1 García-Puche, José Luis
A1 Robles-Fernández, Inmaculada
A1 Exposito, José
A1 Martorell-Marugan, Jordi
A1 Carmona-Sáez, Pedro
A1 Garrido-Navas, María del Carmen
A1 Rolfo, Christian
A1 Ilyine, Hugh
A1 Lorente, José Antonio
A1 Legueren, Marta
A1 Serrano, María José
K1 Exosomes
K1 MicroRNA
K1 Circulating tumor cells
K1 Localized breast cancer
K1 Neoadjuvant chemotherapy
K1 Conservative surgery
K1 Cancer diagnosis
K1 Cancer prognosis
K1 Exosomas
K1 Células neoplásicas circulantes
K1 Neoplasias de la mama
K1 Terapia neoadyuvante
K1 Pronóstico
K1 Diagnóstico
AB Background: Breast cancer patients under neoadjuvant chemotherapy includes a heterogeneous group of patients who eventually develop distal disease, not detectable by current methods. We propose the use of exosomal miRNAs and circulating tumor cells as diagnostic and predictive biomarkers in these patients.Methods: Fifty-three breast cancer women initially diagnosed with localized breast cancer under neoadjuvant chemotherapy were prospectively enrolled in this study. However, six of them were later re-evaluated and diagnosed as metastatic breast cancer patients by PET-CT scan. Additionally, eight healthy donors were included. Circulating tumor cells and serum exosomal miRNAs were isolated from blood samples before and at the middle of neoadjuvant therapy and exosomal miRNA levels analyzed by qPCR.Results: Before neoadjuvant therapy, exosomal miRNA-21 and 105 expression levels were higher in metastatic versus non-metastatic patients and healthy donors. Likewise, higher levels of miRNA-222 were observed in basal-like (p = 0.037) and in luminal B versus luminal A (p = 0.0145) tumor subtypes. Exosomal miRNA-222 levels correlated with clinical and pathological variables such as progesterone receptor status (p = 0.017) and Ki67 (p = 0.05). During neoadjuvant treatment, exosomal miRNA-21 expression levels directly correlated with tumor size (p = 0.039) and inversely with Ki67 expression (p = 0.031). Finally, higher levels of exosomal miRNA-21, miRNA-222, and miRNA-155 were significantly associated with the presence of circulating tumor cells.Conclusion: Liquid biopsies based on exosomal miRNAs and circulating tumor cells can be a complementary clinical tool for improving breast cancer diagnosis and prognosis.
PB BioMed Central Ltd.
SN 1465-5411
YR 2019
FD 2019-02-06
LK http://hdl.handle.net/10668/3152
UL http://hdl.handle.net/10668/3152
LA en
NO Rodríguez-Martínez A, de Miguel-Pérez D, Ortega FG, García-Puche JL, Robles-Fernández I, Exposito J, et al. Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy. Breast Cancer Res. 2019 Feb 6;21(1):21.
DS RISalud
RD Apr 18, 2025